Misset J L, Mathé G, Tubiana M, Caillou B, de Vassal F, Pouillart P, Gil M, Tentas C, Hayat M, Schwarzenberg L, Jasmin C, Delgado M, Machover D, Ribaud P, Musset M
Cancer Chemother Pharmacol. 1978;1(4):197-202. doi: 10.1007/BF00257149.
We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall complete remission rate was about 79% for lymphosarcoma and 73% for reticulosarcoma. About 50% of the patients were still in remission in each of the two diseases at 2 years; 60% of lymphosarcoma and 44% of reticulosarcoma patients achieved 2-year survival. This study shows the prognostic value of the WHO classification for lymphosarcoma and reticulosarcoma: the prognosis of prolymphocytic (centrofollicular) lymphosarcoma is far better than that of the lymphoblastic type, which is in turn better than that of the very poor prognosis of the immunoblastic type. The prognosis of reticulosarcoma is intermediate between that of the best-prognosis and that of the poorest-prognosis type of lymphosarcoma.
我们根据一项联合初始化疗、针对“冰山”部位的辅助放疗、补充化疗以及最终的主动免疫疗法的方案，对101例初发或复发的晚期（III期和IV期）淋巴肉瘤和网状细胞肉瘤患者进行了治疗。淋巴肉瘤的总体完全缓解率约为79%，网状细胞肉瘤为73%。两种疾病中各约50%的患者在2年时仍处于缓解状态；60%的淋巴肉瘤患者和44%的网状细胞肉瘤患者实现了2年生存。本研究显示了世界卫生组织（WHO）分类对淋巴肉瘤和网状细胞肉瘤的预后价值：前淋巴细胞（中心滤泡性）淋巴肉瘤的预后远优于淋巴母细胞型，而淋巴母细胞型又优于免疫母细胞型的极差预后。网状细胞肉瘤的预后介于淋巴肉瘤最佳预后类型和最差预后类型之间。
